Novartis halts malaria drug trial amid participant shortfall

Covid-19Novartis halts malaria drug trial amid participant shortfall

Date:

Novartis halts malaria drug trial amid participant shortfall

Swiss drugmaker Novartis is halting its trial of malaria drug hydroxychloroquine (HCQ) against COVID-19 after struggling to find participants, it said on Friday, as data emerged from other studies raising doubts about the drug’s efficacy.

Novartis’ trial began in April and sought to test the drug in 440 hospitalized patients. But the project only managed to recruit a handful.

“The recruitment challenge facing our hydroxychloroquine trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable time frame to determine the efficacy of hydroxychloroquine in treating patients with COVID-19,” Novartis said in a statement.

Share post:

Subscribe

Popular

More like this
Related

Tips To Protect Your Eyes During Holi

Lifestyle News: Holi is approaching, and people have started...

Can SIPs generate inflation-beating returns?

Inflation can be a significant roadblock in a long-term...

Which Relationship Last Longer? Know Here!

Lifestyle Desk— A relationship is a beautiful experience. But...

Google Pixel 9 Series will be three models: A closer look at the details!

Tech Desk— Google Pixel 9 Series has always been...